Pfizer has low forward P/E ratios for the next five years. The FY2027 forward P/E ratio is low at 8.61. On the other hand, we see that the ratio will not shrink significantly between FY2024 and FY2027 ...

Yet, despite recently beating analysts' expectations for the third quarter on both the top and bottom lines -- while also raising full-year guidance -- Zoetis' share price has slid 12% in the last ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...